Lollmaorofl
2021-12-22
Ah shit definitely not the best news for Merck...
France cancels order for Merck's COVID-19 antiviral drug
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691619412,"tweetId":"691619412","gmtCreate":1640182435454,"gmtModify":1640183732848,"author":{"id":3573124081715681,"idStr":"3573124081715681","authorId":3573124081715681,"authorIdStr":"3573124081715681","name":"Lollmaorofl","avatar":"https://static.tigerbbs.com/d359f1ef78d2115b312a9a26806c1e40","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ah shit definitely not the best news for Merck...</p></body></html>","htmlText":"<html><head></head><body><p>Ah shit definitely not the best news for Merck...</p></body></html>","text":"Ah shit definitely not the best news for Merck...","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691619412","repostId":2193019234,"repostType":4,"repost":{"id":"2193019234","kind":"news","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8 <a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4007":"制药","MRK":"默沙东","PFE":"辉瑞","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":988,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691619412"}
精彩评论